FDA
-
-
-
-
-
-
-
DICE Therapeutics (DICE) Reports Positive Topline Data from Phase 1 Clinical Trial of DC-806
-
-
-
-
-
-
-
DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis
-
-
-
-
-
-
-
DICE Therapeutics Reports Third Quarter 2021 Financial Results and Recent Highlights
-
-
322,209 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

